Figure 2
From: Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
Combination of HSV1716 with anti-PD-1 antibody significantly prolongs survival with several complete responses in the more immunogenic female M3-9-M tumor model. Female C57BL/6 mice were implanted with 5 × 106 M3-9-M cells subcutaneously and treated with three intratumoral injections of 108 pfu HSV1716 followed by intraperitoneal injections of anti-PD-1 antibody as described in Fig. 1a. (a) Individual tumor volumes of mice treated with anti-PD-1 (green lines; n = 11), HSV1716 (blue lines; n = 12) and combined therapy (red lines; n = 11) plotted against tumor volumes recorded for control mice (black lines; n = 10). (b) Kaplan-Meier survival curves for each treatment group demonstrate the improved efficacy of combining PD-1 blockade with HSV1716 virotherapy in the more immunogenic female M3-9-M model. Mice deemed cured were subsequently re-challenged with M3-9-M injection on their contralateral flank and found to be resistant to new tumor growth (see Fig. S2). Survival data were evaluated for statistical significance with Log-rank Mantel-Cox test.
